Clarithromycin might attenuate the airway inflammation of smoke-exposed asthmatic mice via affecting HDAC2

Min Hao1, Jiangtao Lin1, Jun Shu1

  • 11 Peking University China-Japan Friendship School of Clinical Medicine, Beijing 100029, China ; 2 Peking University China-Japan Friendship School of Clinical Medicine, Beijing 100029, China ; 3 Clinical Research Institute of China-Japan Friendship Hospital, Beijing 100029, China ; 4 Department of Respiratory Diseases, China-Japan Friendship Hospital, Beijing 100029, China ; 5 Graduate School Peking Union Medical College &Chinese Academy of Medical Science, Beijng 100029, China.

Journal of Thoracic Disease
|September 19, 2015
PubMed
Abstract

Insights

Clarithromycin improved airway hyperresponsiveness and inflammation in smoke-exposed asthmatic mice. This suggests macrolides may benefit smokers with refractory asthma, potentially involving HDAC2.

Area of Science:

  • Pulmonary Medicine
  • Pharmacology
  • Immunology

Background:

  • Smoke exposure exacerbates asthma, reducing inhaled corticosteroid (ICS) effectiveness.
  • Macrolides exhibit anti-inflammatory and immunomodulatory properties.
  • Previous studies on macrolides for refractory asthma yield conflicting results.

Purpose of the Study:

  • To investigate the therapeutic effects of macrolides on airway inflammation in a mouse model of smoke-exposed asthma.
  • To explore the potential role of Histone Deacetylase 2 (HDAC2) in macrolide treatment response.

Main Methods:

  • Established asthma models in BALB/c mice, including smoke-exposed and clarithromycin-treated groups.
  • Assessed airway hyperresponsiveness (AHR) using lung resistance and compliance measurements.
  • Analyzed lung histopathology, bronchoalveolar lavage fluid (BALF) cell counts, inflammatory cytokines (IL-4, CXCL1), and HDAC2 activity/expression.

Main Results:

  • Clarithromycin significantly improved airway responsiveness (Re, RL, Cdyn) in smoke-exposed asthmatic mice.
  • Reduced inflammatory cell infiltration in lung tissue and BALF (neutrophils, eosinophils) was observed with clarithromycin treatment.
  • Clarithromycin treatment increased HDAC2 activity and expression, while decreasing IL-4 and CXCL1 levels.

Conclusions:

  • Clarithromycin effectively attenuates airway inflammation and improves AHR in a mouse model of smoke-exposed asthma.
  • The therapeutic effects may be mediated through the modulation of HDAC2.
  • Macrolides show promise as an adjunctive therapy for smokers or passive smokers with refractory asthma.

Related Concept Videos

Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
2.3K
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
5.1K
Antiasthma Drugs: Methylxanthines01:24

Antiasthma Drugs: Methylxanthines

Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
2.0K
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.7K
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
4.9K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.3K